Entacapone
Links shared publicly online about this topic
FDA Alert: Stalevo (entacapone/carbidopa/levodopa): Ongoing Safety Review
drugs.com — “FDA Alert: Stalevo (entacapone/carbidopa/levodopa): Ongoing Safety Review” View full resource at drugs.com
Most Recently Shared on March 31, 2010 at 11:30 pm By:
FDA Alert - Stalevo (entacapone/carbidopa/levodopa): Ongoing Safety Review - http://bit.ly/czroqx
FDA Alert: Stalevo(carbidopa/levodopa and entacapone): Ongoing Safety Review: Possible increased cardiovascular risk
drugs.com — “FDA Alert: Stalevo(carbidopa/levodopa and entacapone): Ongoing Safety Review: Possible increased cardiovascular risk” View full resource at drugs.com
Most Recently Shared on August 22, 2010 at 11:37 pm By:
FDA Alert - Ongoing Safety Review: Stalevo (carbidopa/levodopa and entacapone) - http://bit.ly/90MUk2
Stalevo(carbidopa/levodopa and entacapone): Ongoing Safety Review: Possible increased cardiovascular risk
fda.gov — “FDA evaluating clinical trial data that suggest patients taking drug may be at an increased risk for cardiovascular events compared to those taking carbidopa/levodopa” View full resource at fda.gov
Most Recently Shared on August 20, 2010 at 8:05 pm By:
Sandeep Pulim Health Communicator, Physician, and Doctor
#FDA Stalevo(carbidopa/levodopa and entacapone): Ongoing Safety Review: Possible increased cardiovascular risk http://t.co/FTVOYRm
Evidence for the Use of Levodopa--Carbidopa--Entacapone (STALEVO) to Improve Motor Fluctuations in Parkinson--™s Disease | Neurology
touchneurology.com — “Evidence for the Use of Levodopa--Carbidopa--Entacapone (STALEVO) to Improve Motor Fluctuations in Parkinson--™s Disease” View full resource at touchneurology.com
Most Recently Shared on November 12, 2010 at 6:15 pm By:
touchNEURO Neurology and Health Site
Evidence for the Use of Levodopa–Carbidopa–Entacapone (STALEVO) to Improve Motor Fluctuations in Parkinson’s Disease http://ow.ly/363hl
Evidence for the Use of Levodopa"Carbidopa"Entacapone (STALEVO) to Improve Motor Fluctuations in Parkinson's Disease | Neurology
touchneurology.com — “Evidence for the Use of Levodopa"Carbidopa"Entacapone (STALEVO) to Improve Motor Fluctuations in Parkinson's Disease” View full resource at touchneurology.com
Most Recently Shared on October 23, 2009 at 2:41 pm By:
touchNEURO Neurology and Health Site
http://ow.ly/waxS Improve Motor Fluctuations in Parkinson’s Disease #neurology
Medical News: ICPDMD: Early Entacapone Doesn't Delay Dyskinesias in Parkinson's - in Neurology, Parkinson's Disease from MedPage Today
medpagetoday.com — “PARIS -- Adding entacapone (Comtan) to levodopa early in Parkinson's disease does not delay onset of dyskinesias, researchers said here.” View full resource at medpagetoday.com
Most Recently Shared on June 9, 2009 at 9:41 pm By:
NEUROLOGY• ICPDMD: Early Entacapone Doesn't Delay Dyskinesias in Parkinson's (CME/CE) http://tinyurl.com/nsvwnp
FDA evaluating cancer link in Parkinson's drug | Reuters
reuters.com — “NEW YORK (Reuters) - The U.S. Food and Drug Administration is evaluating clinical data that may suggest Novartis AG's Parkinson's disease treatment Stalevo is linked to an increased risk of prostate cancer. Data” View full resource at reuters.com
Most Recently Shared on April 1, 2010 at 2:01 am By:
Hisham Rana, MD Doctor and Physician
FDA evaluating prostate cancer link to Parkinson's drug Stalevo (carbidopa, levodopa, entacapone) http://bit.ly/b6CN8A - #health
Medical News: Cardio Risks Seen With Parkinson's Drug Trio, FDA Says - in Public Health & Policy, FDA General from MedPage Today
medpagetoday.com — “WASHINGTON -- Patients taking the Parkinson's drug combo carbidopa/levodopa and entacapone (Stalevo) may be at a higher risk for cardiovascular events such as myocardial infarction, stroke, and death,” View full resource at medpagetoday.com
Most Recently Shared on August 21, 2010 at 11:12 am By:
Cardio Risks Seen With Parkinson's Drug Trio, FDA Says: WASHINGTON (MedPage Today) -- Patients taking the Parkinso... http://bit.ly/9i1oWN
Impax and GSK Announce Positive Topline Results of ASCEND-PD Phase III Study of IPX066 in Advanced Parkinson's Disease - Drugs.com MedNews
drugs.com — “- IPX066 demonstrated statistically significant improvement over carbidopa-levodopa plus entacapone in reducing the percentage of off time during waking hours A” View full resource at drugs.com
Most Recently Shared on August 15, 2011 at 4:03 pm By:
Drugs and Devices OW OW Health
Impax and GSK Announce Positive Topline Results of ASCEND-PD Phase III Study of IPX066 in Advanced Parkins... http://t.co/UVzIYCu #drug
New Weapons in Fight Against TB? - myOptumHealth
myoptumhealth.com — “Read the news article New Weapons in Fight Against TB? at www.myOptumHealth.com” View full resource at myoptumhealth.com
Most Recently Shared on July 3, 2009 at 9:43 pm By:
New Weapons in Fight Against TB?: Parkinsons drugs may thwart treatment-resistant strain, study finds http://tinyurl.com/mqv87x
DOI Not Found
dx.doi.org — “DOI Not Found” View full resource at dx.doi.org
Most Recently Shared on September 1, 2010 at 11:48 am By:
Erratum: Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDEâ... http://bit.ly/cPA3HD
Parkinson's Drug Under FDA Review: Stalevo Suspected of Upping Cardiovascular Risk - QualityPoint Technologies
qualitypointtech.net — “The cardiovascular status of patients taking a combination of carbidopa/levodopa and entacapone should be checked, but they should not discontinue the drug unless advised to do so by their physician. Medscape Medical News” View full resource at qualitypointtech.net
Most Recently Shared on August 21, 2010 at 2:27 pm By:
Parkinson's Drug Under FDA Review: Stalevo Suspected of Upping Cardiovascular Risk: The cardiovascular status of ... http://bit.ly/aVLMM3
FDA evaluating prostate cancer risk with Stalevo - MPR
empr.com — “The FDA has notified healthcare professionals and patients that it is evaluating data from the long-term STRIDE-PD clinical trial, that may suggest that patients taking Stalevo (carbidopa/levodopa/entacapone, from Novartis) may be at an increased risk for developing prostate cancer.” View full resource at empr.com
Most Recently Shared on March 31, 2010 at 9:07 pm By:
MPR News: FDA evaluating prostate cancer risk with Stalevo: The FDA has notified healthcare professionals and pati... http://bit.ly/aGHNzl
FDA reviews cardiovascular risks associated with Stalevo - MPR
empr.com — “The FDA has notified healthcare professionals that clinical trial data suggesting that Stalevo (carbidopa, levodopa, entacapone, from Novartis) increases the risk for cardiovascular events compared to carbidopa/levodopa (Sinemet, from Bristol-Myers Squibb) is being evaluated.” View full resource at empr.com
Most Recently Shared on August 23, 2010 at 2:12 pm By:
MPR News: FDA reviews cardiovascular risks associated with Stalevo: The FDA has notified healthcare professionals ... http://bit.ly/bTzIjD
FDA reviews cardiovascular risks associated with Stalevo - ONA
oncologynurseadvisor.com — “The FDA has notified healthcare professionals that clinical trial data suggesting that Stalevo (carbidopa, levodopa, entacapone, from Novartis) increases the risk for cardiovascular events compared to carbidopa/levodopa (Sinemet, from Bristol-Myers Squibb) is being evaluated.” View full resource at oncologynurseadvisor.com
Most Recently Shared on August 23, 2010 at 2:08 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
FDA reviews cardiovascular risks associated with Stalevo http://goo.gl/fb/dQsmq
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
Drugs.com
Keeping you up to date with the latest medication news, FDA Medwatch alerts and new drug approvals.
-
Drugs.com
Keeping you up to date with the latest medication news, FDA Medwatch alerts and new drug approvals.
-
Sandeep Pulim
MD, health 2.0, technology, education
Advertisement
